|
Therapy results |
|||||
| Study Group |
Total |
||||
|
|
|||||
| 70 to 75 years |
> 75 years |
||||
|
|
|
||||
| 80 mg/m2 (n = 15) |
90 mg/m2 (n = 14) |
60 mg/m2 (n = 7) |
70 mg/m2 (n = 8) |
(n = 44) |
|
|
|
|||||
| Treatment administered |
|||||
| Chemotherapy cycles |
|||||
| No. |
46 |
42 |
14 |
23 |
125 |
| Median (range) |
2 (1 to 4) |
2 (1 to 5) |
3 (1 to 5) |
3 (1 to 6) |
3 (1 to 6) |
| Vinorelbine (median, mg/m2/wk) |
8.6 |
8.8 |
9.4 |
10.3 |
8.9 |
| Cisplatin (median, mg/m2/wk) |
13.6 |
15.9 |
11.2 |
14.4 |
14.5 |
| Efficacy |
|||||
| Complete response |
- |
- |
- |
1 |
1 |
| Partial response |
8 |
8 |
2 |
3 |
21 |
| Stable disease |
4 |
4 |
3 |
2 |
13 |
| Progressive disease |
2 |
1 |
- |
- |
3 |
| Not evaluated |
1 |
1 |
2 |
2 |
6 |
| Overall response rate (%) |
53 |
57 |
29 |
50 |
50 |
| Time to progression (median, in weeks) |
25.0 |
23.0 |
15.7 |
18.4 |
27.0 |
| Overall Survival |
|||||
| Median (weeks) |
31.0 |
17.3 |
26.6 |
31.7 |
30.1 |
| 1-year (%) |
40.0 |
35.7 |
28.5 |
37.5 |
36.3 |
Pereira et al. BMC Cancer 2004 4:69 doi:10.1186/1471-2407-4-69 |
|||||